Skip to main content
BEONE MEDICINES LTD. logo

BEONE MEDICINES LTD. — Investor Relations & Filings

Ticker · 688235 ISIN · CNE100005XT6 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 727 across all filing types
Latest filing 2025-04-28 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688235

About BEONE MEDICINES LTD.

https://beonemedicines.com/

BEONE MEDICINES LTD. is a biopharmaceutical company focused on the research, development, and commercialization of innovative therapeutic solutions, primarily in the field of oncology. The company specializes in the discovery of targeted small molecule drugs and biologics designed to address unmet medical needs in cancer treatment. Its research and development pipeline emphasizes precision medicine, utilizing advanced molecular biology and medicinal chemistry platforms to identify novel drug candidates. BEONE MEDICINES LTD. aims to improve patient outcomes by developing high-efficacy, low-toxicity therapies that target specific genetic drivers of disease. The company maintains a strong focus on clinical-stage development and strategic collaborations to advance its portfolio of next-generation medicines.

Recent filings

Filing Released Lang Actions
百济神州有限公司董事会决议公告
Regulatory Filings Classification · 95% confidence The document is a board resolution announcement from BeiGene Ltd. dated April 29, 2025. It reports the board's approval of multiple reports and plans, including the 2024 audited financial statements, the 2024 annual report, a fundraising usage report, profit distribution, an action plan for 2025, an evaluation report on the accounting firm, an internal control evaluation report, a sustainability report, and a market value management system. The document itself does not contain the full reports but refers to them being disclosed on the Shanghai Stock Exchange website. The document is relatively short (1673 characters) and serves as an announcement of the board's resolutions and references to the actual reports rather than the reports themselves. Therefore, it fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement of board resolutions and references to multiple reports without containing substantive financial data or the full reports themselves.
2025-04-28 Chinese
2024年百济神州负责任商业和可持续发展报告
Environmental & Social Information Classification · 100% confidence The document is titled "2024年 负责任商业和 可持续发展 报告" which translates to "2024 Responsible Business and Sustainability Report." It contains detailed sections on the company's sustainability initiatives, environmental goals, social responsibility, governance, and related strategies. The content includes management letters, strategic goals, environmental and social impact assessments, and progress updates. There is no indication that this is an annual financial report, earnings release, or regulatory filing. Instead, it aligns with Environmental & Social Information (ESG) reporting. The length and detail confirm it is a full report, not just an announcement or summary. Therefore, the document fits the category of Environmental & Social Information (SR).
2025-04-28 Chinese
百济神州有限公司2024年年度报告
Annual Report Classification · 100% confidence The document is titled "百济神州有限公司2024 年年度报告" which translates to "BeiGene Ltd. 2024 Annual Report." It contains detailed financial data, management discussion and analysis, company governance information, risk factors, and audited financial statements. The document length is 15,000 characters, indicating a comprehensive report rather than a brief announcement. It includes signatures from company officers and auditors, detailed financial tables, and extensive narrative sections typical of an annual report. The presence of audited financial statements and management discussion confirms this is the full annual report for the fiscal year 2024. Therefore, the document fits the definition of an Annual Report (10-K). FY 2024
2025-04-28 Chinese
港股公告：翌日披露报表
Share Issue/Capital Change Classification · 100% confidence The document is a detailed disclosure report about changes in issued shares, treasury shares, share repurchases, and sales of treasury shares by the company. It references specific Hong Kong Stock Exchange Listing Rules (Main Board and GEM) sections 13.25A, 17.27A, 10.06(4)(a), and others, which govern disclosure of share capital changes. The document includes tables showing share counts before and after events, prices per share, and confirmations that the share issuances or transfers were authorized and compliant with regulations. It is not a full financial report, earnings release, or management discussion. It is not an announcement of a report but the actual disclosure of share capital changes. This fits the definition of a Share Issue/Capital Change filing, which covers announcements regarding new share issues, stock splits, or other capital changes.
2025-04-28 Chinese
百济神州有限公司2024年度内部控制评价报告
Audit Report / Information Classification · 95% confidence The document is titled '2024年度内部控制评价报告' which translates to '2024 Internal Control Evaluation Report'. It discusses the evaluation of the company's internal control effectiveness as of December 31, 2024. The content includes detailed descriptions of internal control scope, standards, defect recognition, and remediation status. It is a standalone report focused on internal control evaluation, which is typically considered an audit-related report rather than a full annual or interim financial report. The document length is 3975 characters, which is relatively short but contains substantive content rather than just an announcement or certification. There is no indication that this is an announcement of a report publication or a certification letter. The content aligns with the definition of an Audit Report / Information (AR) as it covers internal control evaluation results and related audit opinions without being a full annual report or interim financial report. FY 2024
2025-04-28 Chinese
百济神州有限公司董事会审计委员会2024年度履职情况报告
Audit Report / Information Classification · 95% confidence The document is titled as the "2024年度履职情况报告" (2024 Annual Performance Report) of the Board Audit Committee of BeiGene Ltd. It details the audit committee's activities, including oversight of external and internal audits, review of financial reports for various periods in 2023 and 2024, evaluation of internal controls, and coordination with auditors. The document references multiple financial reports and audit opinions but does not itself contain full financial statements or detailed financial data. It is a report on the audit committee's supervisory and oversight functions rather than a standalone audit report or annual report. The length is 3267 characters, which is relatively short and consistent with a committee report rather than a full financial report. Therefore, the document fits best as an Audit Report / Information (AR) type, which includes standalone audit reports and related oversight information, excluding full annual reports. FY 2024
2025-04-28 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.